These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 26769227)

  • 21. Which TKI? An embarrassment of riches for chronic myeloid leukemia patients.
    Hughes T; White D
    Hematology Am Soc Hematol Educ Program; 2013; 2013():168-75. PubMed ID: 24319178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib.
    Lau A; Seiter K
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):186-96. PubMed ID: 24456839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging drugs for chronic myeloid leukemia.
    Cilloni D; Messa E; Rotolo A; Saglio G
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):175-84. PubMed ID: 20201747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.
    de Lavallade H; Khoder A; Hart M; Sarvaria A; Sekine T; Alsuliman A; Mielke S; Bazeos A; Stringaris K; Ali S; Milojkovic D; Foroni L; Chaidos A; Cooper N; Gabriel I; Apperley J; Belsey S; Flanagan RJ; Goldman J; Shpall EJ; Kelleher P; Marin D; Rezvani K
    Blood; 2013 Jul; 122(2):227-38. PubMed ID: 23719297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is imatinib still an acceptable first-line treatment for CML in chronic phase?
    Goldman JM; Marin D
    Oncology (Williston Park); 2012 Oct; 26(10):901-7. PubMed ID: 23175995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Practical management of patients with chronic myeloid leukemia.
    Cervantes F; Mauro M
    Cancer; 2011 Oct; 117(19):4343-54. PubMed ID: 21413002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Syed YY; McCormack PL; Plosker GL
    BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
    Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
    J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R; Kimura S
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic myeloid leukemia: overview of new agents and comparative analysis.
    Jain P; Kantarjian H; Cortes J
    Curr Treat Options Oncol; 2013 Jun; 14(2):127-43. PubMed ID: 23572291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase.
    Rosti G; Castagnetti F; Gugliotta G; Palandri F; Baccarani M
    Crit Rev Oncol Hematol; 2012 May; 82(2):159-70. PubMed ID: 21565522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial treatment for patients with CML.
    Goldman JM
    Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence.
    Ciftciler R; Haznedaroglu IC
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):7787-7798. PubMed ID: 34982440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
    Pophali PA; Patnaik MM
    Cancer J; 2016; 22(1):40-50. PubMed ID: 26841016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data.
    Breccia M; Tiribelli M; Alimena G
    Crit Rev Oncol Hematol; 2012 Oct; 84(1):93-100. PubMed ID: 22280914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use patterns of first-line inhibitors of tyrosine kinase and time to change to second-line therapy in chronic myeloid leukemia.
    Machado-Alba JE; Machado-Duque ME
    Int J Clin Pharm; 2017 Aug; 39(4):851-859. PubMed ID: 28508322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.